Trial reportEuropean journal of clinical pharmacology1994
Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.
Trial report in European journal of clinical pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 59 citations in OpenAlex.
- Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.Psychopharmacology · 2007Trial
- Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.British journal of clinical pharmacology · 2006Trial
- Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements.European journal of clinical pharmacology · 2004Trial
- Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.British journal of clinical pharmacology · 1999Trial
- Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers.British journal of clinical pharmacology · 1995Trial
- Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects.European journal of clinical pharmacology · 1995Trial
- Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing.European journal of clinical pharmacology · 1994Trial
- Brain histamine modulates recognition memory: possible implications in major cognitive disorders.British journal of pharmacology · 2020Review
- Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.British journal of pharmacology · 2009Article
- Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.British journal of pharmacology · 2000Article
- Comparative tolerability of second generation antihistamines.Drug safety · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute effect of doses of mizolastine 5, 10, 20 and 40 mg, an active control (clemastine 2 mg) and placebo on actual car driving and psychomotor performance have been compared. Twenty four healthy volunteers were treated according to a double-blind, 6-way cross-over design. In the driving test, lasting about 1 h, lateral position control and speed were continuously measured; the psychomotor test battery, lasting 50 min, comprised critical flicker-fusion frequency, critical instability tracking, divided attention, memory search and choice reaction time, and vigilance studies; and mood changes and possible adverse-effects were rated on visual analogue scales. The results showed a dose-response relationship: mizolastine 40 and 20 mg impaired driving and psychomotor performance. The effect of mizolastine 40 mg on driving was strongly correlated with that of clemastine (r = 0.78) and was comparable to the effect of a blood ethanol level of 0.8 mg.ml-1. Mizolastine 5 mg and 10 mg did not have a significant effect on driving performance and psychomotor tests. It was concluded that at a 10 mg dose of mizolastine, the therapeutic dose, it could be considered a safe anti-histamine, although individual adverse reactions cannot be completely ruled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.